Caxton Associates LP boosted its holdings in Denali Therapeutics Inc (NASDAQ:DNLI) by 28.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 134,047 shares of the company’s stock after purchasing an additional 30,000 shares during the quarter. Denali Therapeutics makes up approximately 0.4% of Caxton Associates LP’s holdings, making the stock its 25th biggest position. Caxton Associates LP owned 0.14% of Denali Therapeutics worth $2,769,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Quantamental Technologies LLC purchased a new stake in shares of Denali Therapeutics during the 4th quarter worth approximately $41,000. Great West Life Assurance Co. Can purchased a new stake in Denali Therapeutics during the 3rd quarter valued at $161,000. Essex Investment Management Co. LLC purchased a new stake in Denali Therapeutics during the 4th quarter valued at $182,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Denali Therapeutics by 13.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,436 shares of the company’s stock valued at $216,000 after buying an additional 1,237 shares during the period. Finally, Jane Street Group LLC purchased a new stake in Denali Therapeutics during the 3rd quarter valued at $218,000. Institutional investors and hedge funds own 71.72% of the company’s stock.

NASDAQ:DNLI opened at $24.42 on Friday. Denali Therapeutics Inc has a fifty-two week low of $12.32 and a fifty-two week high of $25.05. The firm has a market cap of $2.33 billion, a P/E ratio of -62.62 and a beta of 2.11.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Tuesday, March 12th. The company reported $0.79 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.90. Denali Therapeutics had a negative return on equity of 7.29% and a negative net margin of 28.06%. The company had revenue of $125.68 million for the quarter, compared to analyst estimates of $9.73 million. As a group, equities analysts forecast that Denali Therapeutics Inc will post -1.65 earnings per share for the current fiscal year.

In other Denali Therapeutics news, COO Alexander O. Schuth sold 7,500 shares of the stock in a transaction on Friday, January 11th. The stock was sold at an average price of $20.37, for a total value of $152,775.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Ryan J. Watts sold 18,333 shares of the stock in a transaction on Friday, January 4th. The stock was sold at an average price of $19.43, for a total value of $356,210.19. The disclosure for this sale can be found here. Insiders have sold a total of 77,500 shares of company stock worth $1,571,274 in the last 90 days. 21.30% of the stock is currently owned by insiders.

Several analysts recently weighed in on DNLI shares. Cantor Fitzgerald restated a “buy” rating and set a $25.00 price target on shares of Denali Therapeutics in a report on Friday, December 7th. Zacks Investment Research upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a report on Thursday, January 3rd. Finally, ValuEngine lowered Denali Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 29th.

ILLEGAL ACTIVITY WARNING: This piece was reported by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2019/03/16/denali-therapeutics-inc-dnli-holdings-lifted-by-caxton-associates-lp.html.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Recommended Story: Why do companies issue convertible shares?

Institutional Ownership by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.